Afficher la couverture 'Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183 | de Vries, Laura, E' en grand format
/5

0 avis

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

Archive ouverte

de Vries, Laura, E | Jansen, Patrick, a M | Barcelo, Catalina | Munro, Justin | Verhoef, Julie, M J | Pasaje, Charisse, Flerida A | Rubiano, Kelly | Striepen, Josefine | Abla, Nada | Berning, Luuk | Bolscher, Judith, M | Demarta-Gatsi, Claudia | Henderson, Rob, W M | Huijs, Tonnie | Koolen, Karin, M J | Tumwebaze, Patrick, K | Yeo, Tomas | Aguiar, Anna, C C | Angulo-Barturen, Iñigo | Churchyard, Alisje | Baum, Jake | Fernández, Benigno, Crespo | Fuchs, Aline | Gamo, Francisco-Javier | Guido, Rafael, V C | Jiménez-Diaz, María, Belén | Pereira, Dhelio, B | Rochford, Rosemary | Roesch, Camille | Sanz, Laura, M | Trevitt, Graham | Witkowski, Benoît | Wittlin, Sergio | Cooper, Roland, A | Rosenthal, Philip, J | Sauerwein, Robert, W | Schalkwijk, Joost | Hermkens, Pedro, H H | Bonnert, Roger, V | Campo, Brice | Fidock, David, A | Llinás, Manuel | Niles, Jacquin, C | Kooij, Taco, W A | Dechering, Koen, J

Edité par CCSD ; Nature Publishing Group -

International audience. Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our studies demonstrate attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound shows single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocks P. falciparum transmission to Anopheles mosquitoes. Genetic and biochemical studies identify AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183. Pharmacokinetic-pharmacodynamic modelling predict that a single 30 mg oral dose is sufficient to cure a malaria infection in humans. Toxicology studies in rats indicate a > 30-fold safety margin in relation to the predicted human efficacious exposure. In conclusion, MMV693183 represents a promising candidate for further (pre)clinical development with a novel mode of action for treatment of malaria and blocking transmission.

Suggestions

Du même auteur

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Archive ouverte | Baragaña, Beatriz | CCSD

International audience. Malaria and cryptosporidiosis, caused by apicomplexan parasites, remain major drivers of global child mortality. New drugs for the treatment of malaria and cryptosporidiosis, in particular, a...

Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

Archive ouverte | Stokes, Barbara, H. | CCSD

International audience. The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failure across Southeast Asia. In Africa, K13- pro...

Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans

Archive ouverte | Malmquist, Nicholas | CCSD

International audience. Current antimalarials are under continuous threat due to the relentless development of drug resistance by malaria parasites. We previously reported promising in vitro parasite-killing activit...

Chargement des enrichissements...